Literature DB >> 11451168

Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study.

S Frachon1, G Gouysse, J Dumortier, A Couvelard, M Nejjari, F Mion, F Berger, P Paliard, O Boillot, J Y Scoazec.   

Abstract

BACKGROUNDS/AIMS: Hepatocellular carcinoma usually contains continuous capillary vessels lacking the differentiation markers specific for normal sinusoidal endothelial cells. We therefore aimed to search for alterations in endothelial cell marker expression in precancerous liver lesions.
METHODS: Expression of the endothelial cell markers CD31, CD34 and BNH9 was analyzed in 138 dysplastic lesions from 40 cirrhotic patients (20 with and 20 without hepatocellular carcinoma).
RESULTS: No expression of the three endothelial cell markers was detected in cirrhotic nodules and in non dysplastic regenerative macronodules. The three markers were detected in 29.8% of dysplastic lesions and 47% of hepatocellular carcinomas. At least one marker was detected in 75% of dysplastic lesions and 100% of hepatocellular carcinomas. The three markers were more frequently expressed in areas of small cell than of large cell change (34 vs 10%). No correlation was found with the grade of dysplasia, the occurrence of arterialization and the association with hepatocellular carcinoma.
CONCLUSIONS: Alterations in the hepatic microcirculation comparable to those observed in hepatocellular carcinoma are present in a significant proportion of dysplastic lesions of the liver and may be indirect markers of the process of liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451168     DOI: 10.1016/s0168-8278(01)00049-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Yasuhide Ikenaka; Kosuke Kaji; Yusaku Shirai; Yosuke Aihara; Junichi Yamao; Masahisa Toyohara; Akira Mitoro; Masayoshi Sawai; Motoyuki Yoshida; Chie Morioka; Masao Fujimoto; Masahito Uemura; Hideto Kawaratani; Tatsuhiro Tsujimoto; Hiroshi Fukui
Journal:  Oncol Lett       Date:  2010-10-05       Impact factor: 2.967

2.  Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis.

Authors:  Ivan Chebib; Meer Taher Shabani-Rad; Michelle S Chow; James Zhang; Zu-Hua Gao
Journal:  Biomark Insights       Date:  2007-02-14

3.  Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Kosuke Kaji; Yasuhide Ikenaka; Yusaku Shirai; Tadashi Namisaki; Mitsuteru Kitade; Tatsuhiro Tsujimoto; Hideto Kawaratani; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2009-11-26       Impact factor: 7.527

4.  Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Norihisa Nishimura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2013-11-07       Impact factor: 7.527

5.  Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.

Authors:  Shuzhe Yao; Jianping Zhang; Haiyan Chen; Yan Sheng; Xiaoying Zhang; Zhiyan Liu; Cuijuan Zhang
Journal:  J Histochem Cytochem       Date:  2013-05-16       Impact factor: 2.479

6.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

Authors:  Li-Bo Chen; Jun-Yao Xu; Zhen Yang; Guo-Bin Wang
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

7.  Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Mitsuteru Kitade; Kosuke Kaji; Yasuhide Ikenaka; Tadashi Namisaki; Junichi Yoshii; Koji Yanase; Masaharu Yamazaki; Tatsuhiro Tsujimoto; Takemi Akahane; Hideto Kawaratani; Masahito Uemura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2009-03-25       Impact factor: 7.527

8.  Microvessel density of malignant and benign hepatic lesions and MRI evaluation.

Authors:  Jian-Ping Lu; Jian Wang; Tao Wang; Yi Wang; Wei-Qing Wu; Li Gao
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

Review 9.  Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges.

Authors:  Stavros C Efremidis; Prodromos Hytiroglou; Osamu Matsui
Journal:  Eur Radiol       Date:  2007-07-06       Impact factor: 5.315

10.  Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Masaharu Yamazaki; Yasuhide Ikenaka; Masayoshi Sawai; Masatoshi Ishikawa; Hideto Kawaratani; Tsuyoshi Mashitani; Mitsuteru Kitade; Kosuke Kaji; Masahito Uemura; Junichi Yamao; Masao Fujimoto; Akira Mitoro; Masahisa Toyohara; Motoyuki Yoshida; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.